Niche platform Starpharma specializes in dendrimer-based biopharmaceuticals including DEP drug delivery and VivaGel, suggesting sales opportunities with pharma companies seeking targeted delivery platforms, antiviral strategies, and novel medical products.

Phase stage assets With DEP cabazitaxel advancing as a phase 2 cancer treatment and recent patent activity, there is potential for collaboration or licensing discussions with oncology players seeking innovative nanoparticle drug formulations.

Strategic partnerships Existing research collaborations, such as the DEP ADC agreement with MSD, indicate openness to co-development and sponsored research, presenting avenues for new MSD-like partners or biotech firms seeking translational oncology partnerships.

Antiviral focus Starpharma’s investments in respiratory virus programs and Viraleze nasal spray positioning create opportunities to engage with infectious disease and respiratory health strategists, government health agencies, and medical device or consumer health channels.

Global market positioning Operating with global reach and significant IP, Starpharma is well-placed to attract licensees or investors interested in emerging nanotechnology-enabled therapeutics, creating sales leads in oncology, antiviral, and delivery technology sectors.